Last, we evaluated the therapeutic effects of individual or combination therapy with the KAT7 inhibitor WM-3835 and the EGFR inhibitor Erlotinib on orthotopic GSC11 and GBM6 tumor xenograft models (Fig. 7d). Here, KAT7 is linked to neoplasm.